Cargando…

A phase II trial protocol of Tocilizumab in anti-TNF refractory patients with JIA-associated uveitis (the APTITUDE trial)

BACKGROUND: Juvenile idiopathic arthritis (JIA) is the most common rheumatic disease in children. Children with JIA are at risk of intraocular inflammation (uveitis). In the initial stages of mild-moderate inflammation uveitis is asymptomatic. Most children with mild-moderate uveitis are managed on...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ramanan, Athimalaipet V., Dick, Andrew D., Jones, Ashley P., Guly, Catherine, Hardwick, Ben, Hickey, Helen, Lee, Richard, McKay, Andrew, Beresford, Michael W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390576/ https://www.ncbi.nlm.nih.gov/pubmed/30886955 http://dx.doi.org/10.1186/s41927-018-0010-2

Ejemplares similares

Tocilizumab in patients with anti-TNF refractory juvenile idiopathic arthritis-associated uveitis (APTITUDE): a multicentre, single-arm, phase 2 trial
por: Ramanan, Athimalaipet V, et al.
Publicado: (2020)

A randomised controlled trial of the clinical effectiveness, safety and cost-effectiveness of adalimumab in combination with methotrexate for the treatment of juvenile idiopathic arthritis associated uveitis (SYCAMORE Trial)
por: Ramanan, Athimalaipet V, et al.
Publicado: (2014)

Outcomes of non-infectious Paediatric uveitis in the era of biologic therapy
por: Cann, Megan, et al.
Publicado: (2018)

The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data
por: Davies, Rebecca, et al.
Publicado: (2020)

Juvenile Idiopathic Arthritis Associated Uveitis
por: Carlsson, Emil, et al.
Publicado: (2021)

Abatacept for severe anti-TNF-alfa refractory JIA-associated uveitis: one year follow-up
por: Alpigiani, MG, et al.
Publicado: (2011)

The efficacy and safety of Tocilizumab in adults with refractory systemic onset JIA
por: Deslypere, G, et al.
Publicado: (2011)

Clinical effectiveness and safety of baricitinib for the treatment of juvenile idiopathic arthritis-associated uveitis or chronic anterior antinuclear antibody-positive uveitis: study protocol for an open-label, adalimumab active-controlled phase 3 clinical trial (JUVE-BRIGHT)
por: Ramanan, Athimalaipet V., et al.
Publicado: (2021)

Treat to Target (Drug-Free) Inactive Disease in JIA: To What Extent Is This Possible?
por: Ramanan, Athimalaipet V., et al.
Publicado: (2022)

Refractory Uveitis in Patient with Castleman Disease Successfully Treated with Tocilizumab
por: Oshitari, Toshiyuki, et al.
Publicado: (2012)

Juvenile idiopathic arthritis-associated uveitis
por: Clarke, Sarah L. N., et al.
Publicado: (2016)

Histone antibodies as a biomarker of uveitis in JIA
por: Nordal, Ellen B, et al.
Publicado: (2014)

Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
por: Acharya, Nisha R., et al.
Publicado: (2020)

Outcome of adalimumab monotherapy in paediatric non-infectious uveitis
por: Al-Julandani, DA, et al.
Publicado: (2023)

Cross sectional, qualitative thematic analysis of patient perspectives of disease impact in juvenile idiopathic arthritis-associated uveitis
por: Sen, Ethan S., et al.
Publicado: (2017)

Adalimumab and severe uveitis in juvenile idiopathic arthritis (JIA) therapy
por: Alpigiani, MG, et al.
Publicado: (2008)

Infliximab to treat chronic uveitis in juvenile idiopathic arthritis (JIA)
por: Bracaglia, C, et al.
Publicado: (2008)

KIR-HLA class I combinations in JIA-associated uveitis
por: Parsa, Miriam, et al.
Publicado: (2012)

High levels of TNFα in patients with COVID-19 refractory to tocilizumab
por: Danlos, F.X., et al.
Publicado: (2021)

Successful treatment of Behçet’s uveitis with Tocilizumab
por: Alokaily, F., et al.
Publicado: (2017)

Intravenous tocilizumab in idiopathic pediatric uveitis with refractory cystoid macular edema – A case report
por: Babu, Kalpana, et al.
Publicado: (2019)

Rituximab in ANA positive polyarticular juvenile idiopathic arthritis (JIA) with uveitis
por: Baildam, EM, et al.
Publicado: (2008)

Psychological Effects and Quality of Life in Parents and Children with Jia-Associated Uveitis
por: Guerriero, Silvana, et al.
Publicado: (2022)

Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)
por: Foeldvari, Ivan, et al.
Publicado: (2019)

Towards molecular-pathology informed clinical trials in childhood arthritis to achieve precision medicine in juvenile idiopathic arthritis
por: Wedderburn, Lucy R, et al.
Publicado: (2023)

Outcome of repeat dosing of sJIA patients with tocilizumab in one UK centre
por: Livermore, P, et al.
Publicado: (2008)

Randomized Trial of Tocilizumab in the Treatment of Refractory Adult Polymyositis and Dermatomyositis
por: Oddis, Chester V., et al.
Publicado: (2022)

PReS-FINAL-2159: Tocilizumab (TCZ) dosing in juvenile idiopathic arthritis (JIA): optimising for different JIA type and body weight patients
por: Lu, P, et al.
Publicado: (2013)

Correction to: Proposal for a definition for response to treatment, inactive disease and damage for JIA associated uveitis based on the validation of a uveitis related JIA outcome measures from the Multinational Interdisciplinary Working Group for Uveitis in Childhood (MIWGUC)
por: Foeldvari, Ivan, et al.
Publicado: (2020)

PReS-FINAL-2112: Mapping the treatment effect of infliximab on a case of refractory anterior uveitis related to juvenile idiopathic arthritis (JIA)
por: Miranda, V, et al.
Publicado: (2013)

Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
por: Joos, R, et al.
Publicado: (2011)

Characteristics of a cohort of children with Juvenile Idiopathic Arthritis and JIA-associated Uveitis
por: Angeles-Han, Sheila T., et al.
Publicado: (2015)

Clinical benefits and potential risks of adalimumab in non‐JIA chronic paediatric uveitis
por: Kouwenberg, Carlyn V., et al.
Publicado: (2021)

Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
por: Renton, William D., et al.
Publicado: (2019)

Tocilizumab for the treatment of systemic onset JIA: a single centre experience from India
por: Sawhney, Sujata, et al.
Publicado: (2012)

PReS-FINAL-2038: Clinical efficacy and tolerability of tocilizumab in patients with persistant systemic JIA
por: Mihailova, D, et al.
Publicado: (2013)

Aptitude testing
por: Hull, Clark Leonard, 1884-1952
Publicado: (1928)

Neurosurgery As An Aptitude
por: Purcărea, Victor Lorin
Publicado: (2019)

Understanding the biology and use of TNF therapy in jia-clinical outcomes
por: Lovell, Daniel, et al.
Publicado: (2014)

Long Term Experience in Patients With JIA-Associated Uveitis in a Large Referral Center
por: Marelli, Luca, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6bs4firh5tqkq7dego023ic4il